Calcipotriol anhydrous

Chemical division

Formula

CERBIOS - PHARMA SA
CAS number: 112965-21-6

 

Synonyms

Calcipotriene anhydrous

 

Background and use

A great deal of activity was devoted during the last years in order to develop analogues of Vitamin D showing the desired cell differenciating and immunomodulating activity, but with strongly reduced hypercalcemic activity.
Calcipotriol was the first Vitamin D analogue on the market and is licensed for once- or twice-daily use in the treatment of moderate plaque psoriasis.
It is available as scalp lotion, cream or ointment.
Combination of Calcipotriol with a potent steroid (Betamethasone) is more effective and is better tolerated.
Synergy with other treatments, like PUVA, UVB and ciclosporin has been reported in some studies.

 

    • High Potency Active Ingredients (HPAI)
    • Drug
      Substance
    • Patent
    • DMF
    • CEP
    • Calcipotriol anhydrous
    • •
    • •
    • •

 

Regulatory compliance

Cerbios-Pharma’s calcipotriol anhydrous is complying to the European Pharmacopoeia. EDMF and US-DMF are available, active and updated. An application for the Certificate of Suitability of the European Pharmacopoeia at the European Directorate for the Quality of Medicines (EDQM) was filed recently.

 

Packaging information

The API is packed in 2, 20, 50 or 100mL brown, type 1 glass bottles with rubber closure and aluminium crimp cap.